Enhanced plasma protein carbonylation in patients with myelodysplastic syndromes

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F17%3A00011729" target="_blank" >RIV/00023736:_____/17:00011729 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1016/j.freeradbiomed.2017.03.007" target="_blank" >http://dx.doi.org/10.1016/j.freeradbiomed.2017.03.007</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.freeradbiomed.2017.03.007" target="_blank" >10.1016/j.freeradbiomed.2017.03.007</a>

Result language
angličtina
Original language name
Enhanced plasma protein carbonylation in patients with myelodysplastic syndromes
Original language description
Myelodysplastic syndromes (MDS) represent a heterogeneous group of pre-leukemic disorders, characterized by ineffective hematopoiesis and the abnormal blood cell development of one or more lineages. Oxidative stress, as an important factor in the carcinogenesis of onco-hematological diseases, is also one of the known factors involved in the pathogenesis of MDS. An increase of reactive oxygen species (ROS) may lead to the oxidation of DNA, lipids, and proteins, thereby causing cell damage. Protein carbonylation caused by ROS is defined as an irreversible post-translational oxidative modification of amino acid side chains, and could play an important role in signaling processes.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
<a href="/en/project/GBP205%2F12%2FG118" target="_blank" >GBP205/12/G118: Nanobiophotonics for future health care</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)